Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
-
Publication number: 20140056808Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.Type: ApplicationFiled: November 29, 2011Publication date: February 27, 2014Applicant: NovelMed Therapeutics, Inc.Inventor: Rekha Bansal
-
Publication number: 20140050661Abstract: The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to the 414H5 and 515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.Type: ApplicationFiled: September 13, 2013Publication date: February 20, 2014Applicant: PIERRE FABRE MEDICAMENTInventors: Christine KLINGUER-HAMOUR, Alexandra Jouhanneaud, Veronique Grenier-Caussanel
-
Publication number: 20140044641Abstract: This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble LY6G6F, VSIG10, TMEM25 and LSR molecules, extracellular domains of LY6G6F, VSIG10, TMEM25 and LSR and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders. This invention further relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LY6G6F, VSIG10, TMEM25 or LSR molecules, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.Type: ApplicationFiled: April 16, 2012Publication date: February 13, 2014Applicant: COMPUGEN LTD.Inventors: Amir Toporik, Amit Novik, Ronen Shemesh
-
Publication number: 20140044639Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.Type: ApplicationFiled: August 15, 2013Publication date: February 13, 2014Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen
-
Publication number: 20140044640Abstract: Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.Type: ApplicationFiled: September 17, 2013Publication date: February 13, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Patent number: 8647636Abstract: Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and methods is substantially lower than dosages conventionally used in the field. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response.Type: GrantFiled: September 4, 2012Date of Patent: February 11, 2014Assignee: Auburn UniversityInventors: Yihang Li, Erfan Ullah Chowdhury, Bernhard Kaltenboeck
-
Publication number: 20140037540Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: October 14, 2013Publication date: February 6, 2014Applicant: ABBVIE BIOTHERAPEUTICS INC.Inventors: DEBBIE LAW, KURT GISH
-
Publication number: 20140037539Abstract: The present invention provides compositions comprising a therapeutically effective combination of radionuclide-labeled anti-EpCAM, radionuclide-labeled anti-EGFR, and radionuclide labeled anti-Tag-72, or their respective antigen binding portions, and a pharmaceutically acceptable carrier, and method of use thereof for the treatment of breast cancer.Type: ApplicationFiled: July 29, 2013Publication date: February 6, 2014Inventors: Roger W. Howell, John M. Akudugu, Jordan B. Pasternack
-
Patent number: 8636981Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: GrantFiled: December 7, 2011Date of Patent: January 28, 2014Assignee: Onclave TherapeuticsInventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall
-
Publication number: 20140023584Abstract: It is intended to provide a novel contrast agent for photoacoustic imaging that is highly capable of binding to a target molecule and generates high photoacoustic signals. The present invention provides a contrast agent for photoacoustic imaging represented by Formula 1: MNP-((L)l-(P)m)n??(Formula 1) (wherein MNP represents a particle containing an iron oxide particle; L represents a linker molecule; P represents a ligand molecule; l represents 0 or 1; and m and n represent an integer of 1 or larger), the contrast agent for photoacoustic imaging including: a particle containing an iron oxide particle that absorbs light in a near-infrared region; and at least one or more ligand molecule(s) immobilized on the particle containing an iron oxide particle, wherein the immobilization density of the ligand molecule is equal to or higher than the cell surface density of a target molecule.Type: ApplicationFiled: September 24, 2013Publication date: January 23, 2014Inventors: Fumio Yamauchi, Satoshi Ogawa, Kengo Kanazaki, Sachiko Inoue, Tatsuki Fukui, Masato Minami, Mayuko Kishi
-
Publication number: 20140017167Abstract: The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting pathological cells associated with a solid tumour, wherein the cells express IL1RAP. Further provided are pharmacological compositions comprising the agents of the invention and methods of using the same.Type: ApplicationFiled: January 19, 2012Publication date: January 16, 2014Applicant: CANTARGIA ABInventors: Thoas Fioretos, Marcus Jaras
-
Publication number: 20140017166Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.Type: ApplicationFiled: April 25, 2013Publication date: January 16, 2014Applicants: AMGEN, INC., U3 PHARMA GMBHInventors: U3 PHARMA GMBH, AMGEN, INC.
-
Patent number: 8628749Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer—and in particular B-cell malignancies—are aspects of the present invention.Type: GrantFiled: January 28, 2011Date of Patent: January 14, 2014Assignee: Nordic Nanovector ASInventors: Roy H. Larsen, Jostein Dahle, Øyvind S Bruland
-
Publication number: 20140010756Abstract: This invention relates to a pharmaceutical composition for inhibiting the growth and/or metastasis of invasive pancreatic cancer in a subject, comprising a molecular-targeted anticancer agent and a pharmaceutically acceptable carrier, wherein the molecular-targeted anticancer agent is a conjugate of a toxin or cytotoxic agent and an antibody or fragment thereof which immunologically and specifically binds to a cell-surface folate receptor ? (FR?) protein of an FR? (+) macrophage that exists around pancreatic cancer cells at the invasive front, and to a diagnostic agent and kit for determining the degree of malignancy of pancreatic cancer or the presence of invasive pancreatic cancer, characterized by determining that the cancer tissue is invasive and metastatic when FR? (+) macrophage is distributed around pancreatic cancer cells at the invasive front.Type: ApplicationFiled: March 16, 2012Publication date: January 9, 2014Inventors: Sonshin Takao, Takami Matsuyama
-
Patent number: 8623328Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.Type: GrantFiled: August 9, 2012Date of Patent: January 7, 2014Assignee: Shanghai Cancer InstituteInventors: Wenxin Qin, Haitao Zhang, Yanjun Yu, Haiyan You, Shengli Yang, Jianren Gu, Gang Huang, Shile Sheng, Tao Chen
-
Patent number: 8623349Abstract: Exemplary embodiments disclosed herein include a microorganism that produces, secretes and injects recombinant antibodies into eukaryote cells said the described microorganisms can be used to prepare pharmaceutical compositions for the treatment of human or veterinary diseases.Type: GrantFiled: March 12, 2008Date of Patent: January 7, 2014Assignee: Consejo Superior de Investigaciones CientificasInventors: Luis Angel Fernandez Herrero, Ana Blanco Toribio
-
Publication number: 20140004038Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.Type: ApplicationFiled: December 7, 2012Publication date: January 2, 2014Applicant: Genentech, Inc.Inventors: Anan Chuntharapai, Gregory D. Plowman, Marc Tessier-Lavigne, Yan Wu, Weilan Ye
-
Publication number: 20140004037Abstract: The invention provides isolated stabilized anti-CD20 antibodies and methods of their manufacture and use in diagnosis and treatment animal diseases including human lymphoma, leukemia, and autoimmunity.Type: ApplicationFiled: January 19, 2012Publication date: January 2, 2014Applicant: Therapeutic Proteins, Inc.Inventor: Rosemarie Wilton
-
Patent number: 8613929Abstract: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain bather functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain bather properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.Type: GrantFiled: July 21, 2011Date of Patent: December 24, 2013Assignee: TO-BBB Holding B.V.Inventors: Pieter J. Gaillard, Albertus G. De Boer, Arjen Brink
-
Publication number: 20130336885Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: March 29, 2013Publication date: December 19, 2013Applicant: GENENTECH INC.Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
-
Publication number: 20130336886Abstract: Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.Type: ApplicationFiled: May 25, 2011Publication date: December 19, 2013Applicant: UNC-CHARLOTTEInventor: Pinku Mukherjee
-
Publication number: 20130330275Abstract: Cancer cells are identified and inhibited using agents that bind to epitopes unique to misfolded forms of surface proteins presented by the cancer cells. In one embodiment, cancer cells are identified and treated using antibodies that bind to a YYX epitope available on the misfolded form of the prion protein, PrP, which has been identified on various cancer cell lineages.Type: ApplicationFiled: February 13, 2013Publication date: December 12, 2013Inventor: Neil Roy CASHMAN
-
Publication number: 20130323166Abstract: A method treating dementia of the Alzheimer's type in a patient by administering ionizing radiation to the brain of the patient.Type: ApplicationFiled: March 8, 2013Publication date: December 5, 2013Inventor: William Beaumont Hospital
-
Publication number: 20130323167Abstract: Several agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the accumulation of nanoparticles in tumors. Exemplary vascular-active agents include a bacterium, a pro-inflammatory cytokine, and microtubule-destabilizing drugs. Such agents can increase the tumor to blood ratio of radioactivity by more than 20-fold compared to nanoparticles alone. Moreover, vascular-active agents dramatically improved the therapeutic effect of nanoparticles containing radioactive isotopes or chemotherapeutic agents.Type: ApplicationFiled: October 20, 2011Publication date: December 5, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Bert Vogelstein, Yuan Qiao, Xin Huang, Kenneth Kinzler, Shibin Zhou, Luis Diaz
-
Publication number: 20130323168Abstract: Provided herein are novel compounds based on xanthene, for example biarsenical compounds, which are useful as molecular probes. The compounds contain at least one isotope atom, such as a radioisotope atom. Methods for visualizing tetracysteine-tagged analyte molecules such as proteins using said compounds, methods for synthesizing said compounds, and methods for treating cancer or other hyperproliferative disorders using said compounds are also provided.Type: ApplicationFiled: November 15, 2011Publication date: December 5, 2013Applicant: BIOPERCEPT ABInventors: Hans Eric Peter Strom, Samuel Par Simon Svensson
-
Publication number: 20130315819Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development.Type: ApplicationFiled: May 29, 2013Publication date: November 28, 2013Applicant: COMPUGEN LTD.Inventors: Amir TOPORIK, Anat COHEN-DAYAG, Avi Yeshah ROSENBERG, Eve MONTIA, Galit ROTMAN, Liat DASSA, Meirav BEIMAN, Ofer LEVY, Sergey NEMZER, Shira WALACH, Shirley SAMEACH- GREENWALD, Yaron KINAR, Zurit LEVINE
-
Publication number: 20130315820Abstract: An antibody directed against the BDCA-2 protein for the prevention or the treatment of the pathologies involving activation of the plasmacytoid dendritic cells.Type: ApplicationFiled: December 12, 2011Publication date: November 28, 2013Applicant: LFB BIOTECHNOLOGIESInventors: Nathalie Fournier, Christophe Romeuf
-
Patent number: 8591863Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: GrantFiled: June 20, 2012Date of Patent: November 26, 2013Assignee: Abbvie Biotherapeutics Inc.Inventors: Debbie Law, Kurt Gish
-
Publication number: 20130295008Abstract: The present invention discloses methods for treating non-malignant cell diseases by administering to an individual a construct comprising actinium-225 or bismuth-213 and an antigen of a non-malignant cell. Also, provided is a method for treating a solid tumor associated with an abnormal proliferation of cells by targeting an antigen of the tumor-associated vasculature with the constructs.Type: ApplicationFiled: May 20, 2013Publication date: November 7, 2013Inventors: David A. Scheinberg, Michael R. McDevitt, Dangshe Ma, George Sgouros
-
Publication number: 20130295007Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: April 30, 2013Publication date: November 7, 2013Applicant: GENENTECH, INC.Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
-
Publication number: 20130295006Abstract: Compositions and methods for evaluating a pharmacokinetic property of an ophthalmic agent administered by intravitreal injection are provided.Type: ApplicationFiled: April 23, 2013Publication date: November 7, 2013Inventors: John B. Christoforidis, Michael V. Knopp
-
Publication number: 20130287684Abstract: The present invention relates to novel therapeutic recombinant antibodies directed against HER3 (ErbB3), as well as compositions comprising mixtures of at least two of said recombinant anti-HER3 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.Type: ApplicationFiled: October 31, 2011Publication date: October 31, 2013Applicant: SYMPHOGEN A/SInventors: Mikkel Wandahl Pedersen, Helle Jacobsen, Klaus Koefoed
-
Publication number: 20130287683Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.Type: ApplicationFiled: March 15, 2013Publication date: October 31, 2013Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
-
Patent number: 8568723Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.Type: GrantFiled: July 18, 2011Date of Patent: October 29, 2013Assignee: ZymoGenetics, Inc.Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
-
Publication number: 20130280163Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.Type: ApplicationFiled: August 12, 2011Publication date: October 24, 2013Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
-
Publication number: 20130272957Abstract: The present inventions relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such antibodies and compositions comprising such antibodies for the preparation of a medicament to treat cancer. Diagnosis process and kits are also part of the invention.Type: ApplicationFiled: November 9, 2012Publication date: October 17, 2013Inventor: Liliane GOETSCH
-
Publication number: 20130266510Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages, wherein the cancer is relates to multiple myeloma, including multiple myeloma precursor diseases. This invention further relates to extracellular domains of TMEM154 proteins and variants, and therapeutic usages thereof.Type: ApplicationFiled: September 16, 2011Publication date: October 10, 2013Applicant: Compugen Ltd.Inventors: Gad S. Cojocaru, Haiming Chen, James Berenson
-
Publication number: 20130266511Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.Type: ApplicationFiled: June 6, 2013Publication date: October 10, 2013Inventors: Jascha-Nikolai Rybak, Christoph Rosli, Alessandra Villa, Giovanni Neri, Dario Neri
-
Patent number: 8545850Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.Type: GrantFiled: November 5, 2010Date of Patent: October 1, 2013Assignee: Genentech, Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Publication number: 20130224111Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.Type: ApplicationFiled: April 16, 2013Publication date: August 29, 2013Applicants: National University Corporation Yamaguchi University, National University Corporation Chiba UniversityInventors: National University Corporation Chiba University, National University Corporation Yamaguchi
-
Publication number: 20130224109Abstract: The present invention features compositions for inhibiting both the IL-6 and the IL-21 pathways and methods of making and using such compositions. Our work to date indicates the importance of the redundancy of IL-6 and IL-21 to perform certain crucial functions. The pathways can be inhibited by inhibiting the ligands (i.e., IL-6 and IL-21) and/or their respective receptors (i.e., the IL-6 receptor and IL-21 receptor). Alternatively, or in addition, upstream and downstream effectors in the IL-6 and IL-21 pathways can be blocked. The agents used can be antibody or antibody-based proteins or peptides including circulating receptors, optionally coupled to an immunoglobulin or a portion thereof (e.g., the Fc region). Also provided are methods for using the compositions, for example, in organ transplantation, tissue grafting, or autoimmune disorders.Type: ApplicationFiled: July 20, 2011Publication date: August 29, 2013Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.Inventors: Terry Strom, Maria Koulmanda
-
Publication number: 20130224110Abstract: The present invention relates to a method of increasing blood brain barrier (“BBB”) permeability in a subject. This method involves administering to the subject an agent or agents which activate both of the A1 and A2A adenosine receptors. Also disclosed is a method to decrease BBB permeability in a subject. This method includes administering to the subject an agent which inhibits or blocks the A2A adenosine receptor signaling. Compositions relating to the same are also disclosed.Type: ApplicationFiled: September 16, 2011Publication date: August 29, 2013Applicant: CORNELL UNIVERSITYInventor: Margaret S. Bynoe
-
Publication number: 20130224108Abstract: This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human head and neck squamous cell carcinomas. The invention further relates to binding assays, which utilize the monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. In particular aspects, the CDMAB used in the methods of the invention is an anti-CD44 antibody, which may be the antibody produced by the hybridoma deposited with the ATCC having accession number PTA-4621 and/or a chimeric or humanized version thereof.Type: ApplicationFiled: February 4, 2011Publication date: August 29, 2013Applicants: UNIVERSITY OF MIAMI, HOFFMANN-LA ROCHE INC.Inventors: Luis A.G. Da Cruz, Elizabeth Jane Franzmann
-
Publication number: 20130216475Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.Type: ApplicationFiled: April 2, 2013Publication date: August 22, 2013Applicant: Genentech, Inc.Inventor: Genentech, Inc.
-
Publication number: 20130216476Abstract: The use of an anti-CD71 monoclonal antibody or a fragment of an abovementioned antibody capable of binding to the CD71 antigen for the preparation of a drug intended for the prevention or treatment of myelomas.Type: ApplicationFiled: May 3, 2011Publication date: August 22, 2013Applicant: LFB BIOTECHNOLOGIESInventor: Laurence Boumsell
-
Patent number: 8512754Abstract: A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented.Type: GrantFiled: September 2, 2011Date of Patent: August 20, 2013Inventor: David Needham
-
Patent number: 8512704Abstract: The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27.Type: GrantFiled: July 30, 2010Date of Patent: August 20, 2013Assignee: Genentech, Inc.Inventors: Kerstin Jahn-Hofmann, Sannah Zoffmann Jensen, Hugues Matile, Cristiano Migliorini, Haiyan Wang
-
Patent number: 8512675Abstract: The present invention relates to novel histidine derivates that can be used for the labeling of biomolecules with radioactive metal tricarbonyls. The new derivatives have a histidine that is derivatized at the N? and at least protected at the N? and optionally at the N?; or derivatized at the N? and at least protected at the N? and optionally at the N?; or derivatized at the N? and N? and at least protected at the N? and optionally at the N?; or derivatized at the N?; or derivatized at the N?; or derivatized at the N? and N?; or at least protected at the N? and optionally at the N?.Type: GrantFiled: April 29, 2004Date of Patent: August 20, 2013Assignee: Mallinckrodt LLCInventors: Roger Alberto, Jae Kyoung Pak
-
Publication number: 20130209356Abstract: Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.Type: ApplicationFiled: April 2, 2013Publication date: August 15, 2013Applicant: IMMUNOMEDICS, INC.Inventor: Immunomedics, Inc.
-
Publication number: 20130209355Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: June 8, 2011Publication date: August 15, 2013Applicant: GENMAB A/SInventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren